drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T)
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor targeting mesothelin, enabling MHC-independent recognition and cytotoxic killing of mesothelin-positive tumor cells after reinfusion (typically 1–10×10^6 cells/kg IV; local delivery optional).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor specific for mesothelin, enabling MHC-independent recognition of mesothelin-positive tumor cells. CAR engagement triggers CD3ζ and costimulatory signaling, leading to T-cell activation, cytokine release, proliferation, and targeted cytotoxic killing of mesothelin-expressing cancer cells.
drug_name
Mesothelin-directed CAR-T cells
nct_id_drug_ref
NCT06515626